KR20080008367A - 리포좀에 봉입된 독소루비신으로 진행성 난소암을 치료하는방법 - Google Patents

리포좀에 봉입된 독소루비신으로 진행성 난소암을 치료하는방법 Download PDF

Info

Publication number
KR20080008367A
KR20080008367A KR1020077026950A KR20077026950A KR20080008367A KR 20080008367 A KR20080008367 A KR 20080008367A KR 1020077026950 A KR1020077026950 A KR 1020077026950A KR 20077026950 A KR20077026950 A KR 20077026950A KR 20080008367 A KR20080008367 A KR 20080008367A
Authority
KR
South Korea
Prior art keywords
administering
comprises administering
ovarian cancer
liposomes
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077026950A
Other languages
English (en)
Korean (ko)
Inventor
로날드 디. 알바레즈
마이클 제이. 제이알. 스트라운
Original Assignee
알자 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알자 코포레이션 filed Critical 알자 코포레이션
Publication of KR20080008367A publication Critical patent/KR20080008367A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020077026950A 2005-04-21 2006-04-20 리포좀에 봉입된 독소루비신으로 진행성 난소암을 치료하는방법 Withdrawn KR20080008367A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67418805P 2005-04-21 2005-04-21
US60/674,188 2005-04-21

Publications (1)

Publication Number Publication Date
KR20080008367A true KR20080008367A (ko) 2008-01-23

Family

ID=36811891

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077026950A Withdrawn KR20080008367A (ko) 2005-04-21 2006-04-20 리포좀에 봉입된 독소루비신으로 진행성 난소암을 치료하는방법

Country Status (11)

Country Link
US (1) US20070026060A1 (cg-RX-API-DMAC7.html)
EP (1) EP1874324A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008538584A (cg-RX-API-DMAC7.html)
KR (1) KR20080008367A (cg-RX-API-DMAC7.html)
CN (1) CN101163485A (cg-RX-API-DMAC7.html)
AU (1) AU2006238877A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609939A2 (cg-RX-API-DMAC7.html)
CA (1) CA2605669A1 (cg-RX-API-DMAC7.html)
IL (1) IL186699A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007013056A (cg-RX-API-DMAC7.html)
WO (1) WO2006116341A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
ES2768344T3 (es) 2011-06-17 2020-06-22 Myriad Genetics Inc Métodos y materiales para evaluar el desequilibrio alélico
UY34295A (es) * 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
JP6325453B2 (ja) 2011-12-21 2018-05-16 ミリアド・ジェネティックス・インコーポレイテッド ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
WO2001032145A1 (en) * 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment

Also Published As

Publication number Publication date
WO2006116341A1 (en) 2006-11-02
BRPI0609939A2 (pt) 2010-05-11
CA2605669A1 (en) 2006-11-02
AU2006238877A1 (en) 2006-11-02
IL186699A0 (en) 2008-02-09
EP1874324A1 (en) 2008-01-09
US20070026060A1 (en) 2007-02-01
JP2008538584A (ja) 2008-10-30
MX2007013056A (es) 2008-04-07
CN101163485A (zh) 2008-04-16

Similar Documents

Publication Publication Date Title
Scholl et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6
Misset et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
Hainsworth et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Liu et al. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent
Atiq et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
Souhami et al. High-dose cyclophosphamide in small-cell carcinoma of the lung.
Howell et al. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Zelek et al. Phase II study of oxaliplatin and fluorouracil in taxane-and anthracycline-pretreated breast cancer patients
Rivera et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
US20070026060A1 (en) Method for treating advanced ovarian cancer
Kobayashi et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
Pectasides et al. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer
Mori et al. Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma
Laber et al. A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
Secord et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
WO2006032136A1 (en) Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
WO2001083020A1 (en) Antineoplastic platinum therapeutic method and composition
Zulkowski et al. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine
Fujiwara et al. Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study
Scheithauer et al. Phase II study of amonafide in advanced breast cancer
Alici et al. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC)
Recchia et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer
Que et al. Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer
Veronesi et al. Cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma
Roth et al. Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid